Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
2022 · Journal of Hematology & Oncology · 159 citations
https://doi.org/10.1186/s13045-022-01382-5
D
Didem Özkazanç
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
23
Papers
500
Citations
8
h-index
8
i10-index
Didem Özkazanç is an academic researcher from AIMM Therapeutics (Netherlands). The author has contributed to research in topics: Immune Cell Function and Interaction & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 8, co-authored 20 publications.
Papers by this author
worksAdditional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.21524015
Additional file 4 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.21524021
Additional file 1 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.21524012
Additional file 3 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.21524018
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat